The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Genetic alterations of the PIK3CA gene, encoding the p110α catalytic subunit of PI3Kα, are prevalent across various human cancers.
• Canonical PIK3CA mutations, often found at 3 hotspot locations, lead to PI3K hyperactivation and promote oncogenesis through PI3K/AKT/mTOR and PI3K/COX-2/PGE2 pathways.
• These mutations can serve as predictive biomarkers for response to PI3K inhibitors and NSAID therapy.

Approach:

• This review synthesizes current knowledge on the landscape of PIK3CA mutations in diverse cancers.
• It highlights ongoing research efforts to elucidate the functional properties of non-canonical PIK3CA mutations.
• The review also summarizes findings from clinical trials involving PI3K inhibitors and ongoing studies.

Key Points:

• PIK3CA mutations are significant drivers in numerous cancers, influencing key signaling pathways.
• Understanding non-canonical mutations is crucial for a comprehensive view of PIK3CA's role in oncogenesis.
• Clinical trials are evaluating PI3K inhibitors, with PIK3CA mutation status potentially guiding treatment decisions.

Conclusions:

• PIK3CA mutations represent a critical area of cancer research with therapeutic implications.
• Further investigation into non-canonical mutations will refine our understanding of PI3K pathway dysregulation in cancer.
• Targeted therapies inhibiting PI3K show promise, necessitating continued clinical evaluation and biomarker development.